PWRM, Power 3 Medical Products Inc., PWRM.OB
PWRM is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease).
Alzheimer's disease is among the most well known form of dementia, a broad term when it comes to forgetfulness and other intellectual abilities critical enough to obstruct everyday life. Alzheimer's diseases is the reason for 50 to seventy per cent of dementia cases.
Worldwide, breast cancer consists 10.4% in all cancer occurrence among the ladies, rendering it the most common form of non-skin cancer in females and the fifth most typical reason for cancer death. In '04, breast cancers triggered 519,000 fatalities across the world (7% associated with cancer deaths; practically 1% of all deaths). Breast cancer is roughly a hundred situations more established in females compared to men, despite the fact that males are apt to have poorer successes on account of waiting times in a diagnosis
Parkinson's disease typically has effects on people around fifty. The early signs of PD tend to be subtle and also occur gradually. When it comes to many people the condition moves along more rapidly than in others. The fact that the condition moves along, the shaking, or tremor, which will has an effect on nearly all PD individuals may turn to restrict every day actions. Other signs and symptoms may include depression and other emotional changes; difficulty in swallowing, chewing, and speaking; urinary problems or constipation; skin problems; and sleep disruptions. There are currently no blood or laboratory tests that have been which can support in diagnosing sporadic PD. For that reason the medical diagnosis is determined by track record and a neurological examination. The illness can be tough to diagnose precisely. Physicians may very well sometimes demand brain scans or laboratory tests in order to exclude other diseases.
PWRM has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroProÂ®, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s and ALS diseases, for which it is currently engaged in Phase II clinical trials.
PWRM has filed several patent applications for its NuroProÂ® technology that are currently pending. PWRM also has a world-wide exclusive license from the Baylor College of Medicine in Houston, Texas. To date, PWRM has given 9 presentations on NuroPro at international scientific meetings in the United States, Europe and China, and has published 6 articles in peer-reviewed scientific journals on the subject. PWRM intends to publish these latest findings as well.
PWRM recently reported that it has signed a definitive agreement to acquire all of the stock of Rozetta-Cell Life Sciences, a medical biotechnology company that focuses on the delivery and imaging of stem cells during therapy.
More about PWRM at www.power3medical.com.
WCA Waste Corporation (Nasdaq:WCAA) recently reported that it has signed a purchase agreement to acquire certain assets of Emerald Waste Services.
The assets include two landfills, one transfer station and three hauling operations
China Technology Development Group Corporation (Nasdaq:CTDC), a growing clean energy group based in China to provide solar energy products and solutions, recently reported that its wholly-owned subsidiary, Linsun Power Technology (Quanzhou) Corp. Ltd., has been selected to supply 1.55 megawatts (MW) of transparent multi-crystalline solar modules for two on-grid solar power plants in Molfetta and Verona of Italy.
The transparent solar module is a new product developed by CTDC's subsidiary, with nice appearance and high transparence, especially suitable for Building-Integrated Photovoltaics (BIPV) projects.
Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) and privately held Sarasota Medical Products, Inc. (NYSE:SMP) of Sarasota, FL, recently reported that they signed a Binding Letter of Intent to determine the feasibility of pursuing a joint research and development venture for treating chronic ischemic wounds. The venture will be based on combining Oxygen's Wundecyte(tm) PFC formulation with SMP's topical medical devices.
GRHU, GreenHouse Holdings, Inc., OTCQB:GRHU
GRHU is an integrator of some of the world’s most innovative environmental, public safety, infrastructure technologies.
GRHU provides systems that are financially sound and sustainable to residential, commercial, industrial and government markets around the globe.
GRHU recently reported the signing of multiple contract awards for its Life Protection (NYSE:LPI) Governmental Services Division, totaling $6 million. The recently acquired LPI subsidiary provides innovative training, support, design and construction of facilities and services to meet the needs of the U. S. Government, military, and law enforcement agencies.
Furthermore, GRHU has been engaged to utilize Southern California Edison's (SCE) Automated Demand Response (Auto-DR) program in Gulfstream Aerospace Corporation's Long Beach, CA facility. GRHU is a qualified service provider of SCE's Auto-DR program, providing site assessment, feasibility studies, project development, engineering, and installation of enabling technologies and complete processing of all incentives.
More about GRHU at www.greenhouseintl.com
Signup for FREE Daily Stock Alerts From http://www.CRWEFinance.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (OTCPK:CRWE) has received ten thousand dollars in cash and anticipates another ten thousand dollars in cash from the company for 60 days of advertisement services for Green House Holdings, Inc. (GRHU). In addition to the cash, Crown Equity Holdings Inc. (OTCPK:CRWE) also anticipates receiving 20,000 shares of 144 restricted stocks from a third party. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (OTC:PWRM).